Phase 3 Heart Disease Trial, Recruiting NCT04201015 Sponsor: University of Leeds Condition: Heart Disease
Back to Heart Disease

Phase 3 Heart Disease Trial, Recruiting

NCT04201015
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have heart failure that has been confirmed through clinical assessment, heart ultrasound (echocardiogram), and hormone-level testing
  • People who have a cardiac pacemaker fitted
  • People who are physically able to complete a peak exercise test (an exercise test that measures the heart at maximum effort)
  • People who are willing and able to give their formal consent to take part

Who may not be able to join:

  • People who experience chest pain (angina) that limits how much exercise they can do
  • People whose heart failure symptoms have been unstable, meaning their medications have been changed in the last three months
  • People whose heart ultrasound images are of poor quality (confirm with trial site)
  • People who are currently taking a type of medication called calcium channel blockers (CCBs)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 6 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: John Gierula, PhD, University of Leeds

Phone: 01133926642

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
University of Leeds
Registry
ClinicalTrials.gov
Start date
1 June 2020
Est. completion
31 December 2024

Where this trial is recruiting

🇬🇧 United Kingdom

Primary endpoints

Treadmill walk time

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov